A minor comeback for Novartis’ Zelnorm.
Avandia gets a reprieve, of sorts…to remain on the market, but undoubtedly with a raft of warnings and cautions. Meanwhile, more encouraging data on Actos, which appears to avoid the Avandia effect. And was that data “covered up” earlier??
Bristol and ImClone to push oncology treatment Erbitux into expanded trials.
Combo pills – some fly high (Vytorin), others have a hard time getting off the ground.
The current figurehead for pharma whistleblowing, Dr. Peter Rost, gets a new assignment as a blogging journalist at Brandweek NRx.
Class action lawsuit against Novartis for bias against female employees will proceed.
Very cool – electrical stimulation device in brain “re-awakens” man in a minimally conscious state.